December 7, 2016
Today, Lancet published results from the Phase 2, open-label trial of nusinersen (Spinraza) in infants. This trial initiated in 2013, and patients continue to receive the drug.
The results show that infants as young as five weeks old with the most severe form of spinal muscular atrophy (SMA) - a leading genetic cause of infant...
December 6, 2016
The Miller McNeil Woodruff Foundation awarded $87,000 to Cure SMA, in order to further research that will lead to a treatment and cure for SMA. Their gift will also help fund continued advocacy and awareness intiatives.
The generous donation is made each year by Patrick...
December 5, 2016
Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on Clinical Trial Outcomes in Adults with SMA
Cure SMA-funded researcher, Chad Heatwole, and his team, have published a paper, "What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients".
This project was a pilot study funded by a grant from Cure SMA,...